Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Abnormal vascular structure and function within brain metastases is linked to pembrolizumab resistance

  • Kim, Albert E.
  • Lou, Kevin W.
  • Giobbie-Hurder, Anita
  • Chang, Ken
  • Gidwani, Mishka
  • Hoebel, Katharina
  • Patel, Jay B.
  • Cleveland, Mason C.
  • Singh, Praveer
  • Bridge, Christopher P.
  • Rakin Ahmed, Syed
  • Bearce, Benjamin A.
  • Liu, William
  • Lee, Eudocia Q.
  • Fuster García, Elíes|||0000-0002-0716-8960
[EN] Background. We recently conducted a phase 2 trial (NCT028865685) evaluating intracranial efficacy of pembrolizumab for brain metastases (BM) of diverse histologies. Our study met its primary efficacy endpoint and illustrates that pembrolizumab exerts promising activity in a select group of patients with BM. Given the importance of aberrant vasculature in mediating immunosuppression, we explored the relationship between immune checkpoint inhibitor (ICI) efficacy and vascular architecture in the hopes of identifying potential mechanisms of intracranial ICI response or resistance for BM. Methods. Using Vessel Architectural Imaging, a histologically validated quantitative metric for in vivo tumor vascular physiology, we analyzed dual-echo DSC/DCE MRI for 44 patients on trial. Tumor and peri-tumor cerebral blood volume/flow, vessel size, arterial and venous dominance, and vascular permeability were measured before and after treatment with pembrolizumab. Results. BM that progressed on ICI were characterized by a highly aberrant vasculature dominated by largecaliber vessels. In contrast, ICI-responsive BM possessed a more structurally balanced vasculature consisting of both small and large vessels, and there was a trend toward a decrease in under-perfused tissue, suggesting a reversal of the negative effects of hypoxia. In the peri-tumor region, the development of smaller blood vessels, consistent with neo-angiogenesis, was associated with tumor growth before radiographic evidence of contrast enhancement on anatomical MRI. Conclusions. This study, one of the largest functional imaging studies for BM, suggests that vascular architecture is linked with ICI efficacy. Studies identifying modulators of vascular architecture, and effects on immune activity, are warranted and may inform future combination treatments., A.E.K. is supported by an American Brain Tumor Association Basic Research Fellowship In Honor of Paul Fabbri, the William G. Kaelin, Jr., MD, Physician-Scientist Award of the Damon Runyon Cancer Research Foundation, American Association for Cancer Research Breast Cancer Research Fellowship, and American Society of Clinical Oncology Young Investigator Award. E.F.G. was supported by the European Union s Horizon 2020 Programme: Marie Sklodowska-Curie grant agreement No 844646-GLIOHAB and Spanish State Research Agency, Subprogram for Knowledge Generation (PROGRESS, No PID2021-127110OA-I00). P.K.B is supported by the NCI (1R01CA227156-01, 5R21CA220253-02, and 1R01CA244975-01), Damon Runyon Cancer Research Foundation, and Breast Cancer Research Foundation. Y.Y. is supported by the NIH (1R21AG067562-01 and 1R21GM137227-01). K.E.E. is supported by the European Union's Horizon 2020 Programme: ERC Grant Agreement No. 758657-ImPRESS, South-Eastern Norway Regional Health Authority (Grant Agreements No. 2016102, 2017073, 2013069), and the Norwegian Cancer Society and the FRIPRO Grant Agreements No. 261984, 303249). E.R.G. is supported by R01CA211238-01 and R01CA244975.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Interpreting deep learning models for glioma survival classification using visualization and textual explanations.

  • Osadebey, Michael
  • Liu, Qinghui
  • Emblem, Kyrre E.
  • Fuster García, Elíes|||0000-0002-0716-8960
[EN] Background Saliency-based algorithms are able to explain the relationship between input image pixels and deeplearning model predictions. However, it may be difcult to assess the clinical value of the most important image features and the model predictions derived from the raw saliency map. This study proposes to enhance the interpret¿ ability of saliency-based deep learning model for survival classifcation of patients with gliomas, by extracting domain knowledge-based information from the raw saliency maps. Materials and methods Our study includes presurgical T1-weighted (pre- and post-contrast), T2-weighted and T2-FLAIR MRIs of 147 glioma patients from the BraTs 2020 challenge dataset aligned to the SRI 24 anatomical atlas. Each image exam includes a segmentation mask and the information of overall survival (OS) from time of diag¿ nosis (in days). This dataset was divided into training (n = 118) and validation (n = 29) datasets. The extent of surgi¿ cal resection for all patients was gross total resection. We categorized the data into 42 short (mean µ = 157 days), 30 medium (µ = 369 days), and 46 long (µ = 761 days) survivors. A 3D convolutional neural network (CNN) trained on brain tumour MRI volumes classifed all patients based on expected prognosis of either short-term, mediumterm, or long-term survival. We extend the popular 2D Gradient-weighted Class Activation Mapping (Grad-CAM), for the generation of saliency map, to 3D and combined it with the anatomical atlas, to extract brain regions, brain volume and probability map that reveal domain knowledge-based information. Results For each OS class, a larger tumor volume was associated with a shorter OS. There were 10, 7 and 27 tumor locations in brain regions that uniquely associate with the short-term, medium-term, and long-term survival, respec¿ tively. Tumors located in the transverse temporal gyrus, fusiform, and palladium are associated with short, medium and long-term survival, respectively. The visual and textual information displayed during OS prediction highlights tumor location and the contribution of diferent brain regions to the prediction of OS. This algorithm design feature assists the physician in analyzing and understanding diferent model prediction stages. Conclusions Domain knowledge-based information extracted from the saliency map can enhance the interpret¿ ability of deep learning models. Our fndings show that tumors overlapping eloquent brain regions are associated with short patient survival., This work was supported by The European Union s Horizon 2020 Programmes ERC Grant Agreement No. 758657-ImPRESS, and Marie Skłodowska-Curie grant agreement (No 844646-GLIOHAB). The Norwegian Cancer Society and the Research Council of Norway Grants 303249, 261984, 325971. South-Eastern Norway Regional Health Authority Grants 2021057, 2013069, 2017073. Elies Fuster-Garcia was supported by Spanish State Research Agency, Subprogram for Knowledge Generation (PROGRESS, No PID2021-127110OA-I00).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Biomechanical mapping of tumor growth: A novel method to quantify glioma infiltration and mass effect

  • López-Mateu, Carlos
  • Gómez-Mahiques, María
  • Montosa-Micó, Víctor
  • Gil-Terrón-Rodríguez, Francisco Javier|||0000-0002-3536-6462
  • Garcia-Gomez, Juan M
  • Fuster García, Elíes|||0000-0002-0716-8960
  • Sederevicius, Donatas
  • Emblem, Kyrre E.
[EN] Background: Glioblastoma (GBM) growth can alter surrounding brain tissue through location-dependent physiological changes. Two main growth phenotypes¿(I) infiltrative, characterized by diffuse invasion with minimal mass effect, and (II) proliferative, characterized by pronounced tissue compression¿are recognized, but their quantitative characterization and prognostic impact remain poorly explored. Purpose: To develop and validate a novel MRI-based biomarker, the Dynamic Infiltration Rate (DIR), that quantitatively assesses the balance between tumor volume expansion and peritumoral compression, and to evaluate its prognostic ability for stratifying patients based on overall survival (OS). Methods: The DIR was defined as the ratio between tumor-volume enlargement and mass-effect-induced peritumoral compression. Technical validation was conducted using synthetic datasets with known ground truth spanning realistic infiltrative-proliferative spectra. Clinically, patients were dichotomized into high- and low-infiltration groups using a threshold optimized by maximizing the log-rank statistic for OS. Prognostic evaluation included multivariate Cox regression adjusted for age, sex, and MGMT methylation status. Results: The synthetic dataset validation demonstrated high concordance with ground truth (R² = 0.89). Clinical evaluation indicated significantly improved OS in the low DIR group (median = 35.2 weeks) compared to the high DIR group (median = 16.0 weeks; p = 0.0001). DIR effectively stratified patients based on survival (log-rank p < 0.001, HR = 2.49) and remained an independent prognostic factor on multivariate analysis (HR = 1.45, 95% CI 1.07¿1.85; p = 0.0159). Conclusions: The DIR is a novel and robust quantitative MRI biomarker capable of distinguishing between proliferative and infiltrative GBM phenotypes, independently predicting OS. Early phenotype identification could facilitate personalized treatment strategies and individualized follow-up scheduling., MCIN/AEI (Ministerio de Ciencia, Innovación y Universidades / Agencia Estatal de Investigación), Grant/Award Numbers: PID2024156848OB-I00, PID2021-127110OA-I00, PDC2025-165365-I00, FPU23/02431; Generalitat Valenciana, Grant/Award Numbers: INVEST/2022/298 (ProgramaINVESTIGO), CIAICO/2022/064(Lalaby-Glio), INNEST/2022/87(SINUÉ); European Research Council, Grant/Award Numbers: 758657-ImPRESS, 101213953-CHRONOS; Helse Sør-Øst RHF, Grant/Award Numbers: 2021057, 2017073, 2023050; Research Council of Norway, Grant/Award Numbers: 325971, 261984, 303249, 32543, 356066; Norwegian Cancer Society, Grant/Award Number: 309012 - SAFARI; Universitat Politècnica de València, Grant/Award Number: PAID-01-24(Subprogram1)